Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients

Alberto Matteelli, Mario Regazzi, Paola Villani, Giuseppina De Iaco, Maria Cusato, Anna Cristina C Carvalho, Silvio Caligaris, Lina Tomasoni, Maria Manfrin, Susanna Capone, Giampiero Carosi

Research output: Contribution to journalArticlepeer-review


Rifampicin (RIF) decreases serum concentrations of several antiretroviral drugs. We carried out a prospective, comparative study to define efavirenz (EFV) pharmacokinetics in 16 cases and 13 controls. Cases were HIV and tuberculosis (TB) co-infected adults assuming RIF 600 mg once daily and EFV 800 mg once daily. Patients on EFV at standard 600 mg dose without RIF were taken as controls. EFV levels in plasma were assayed by high-performance liquid chromatography (HLPC) predose (Ctrough) and at 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 16, 18, 22 and 24 hours post-dose, and pharmacokinetic parameters were determined by non-compartmental methods. Among cases, 81% were males, mean age was 37 years, 50% were Caucasians, mean weight was 64 kg, mean CD4 cell counts and log HIV RNA copies were 160/μ1 and 5.2/μ1, respectively. Cases had a significantly higher C1/F/kg if compared with controls (0.269 ± 0.12 versus 0.167 ± 0.05 L/h/kg, p 60 kg in Europe. Therapeutic drug monitoring may be beneficial for patients on combination therapy with RIF.

Original languageEnglish
Pages (from-to)349-353
Number of pages5
JournalCurrent HIV Research
Issue number3
Publication statusPublished - May 2007


  • Efavirenz
  • HIV infection
  • Pharmacokinetic interaction
  • Rifampicin

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients'. Together they form a unique fingerprint.

Cite this